Advertisement

 

 

Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II.

Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II.
Author Information (click to view)

Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V,


Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V, (click to view)

Bailey JJ, Schirrmacher R, Farrell K, Bernard-Gauthier V,

Advertisement

Expert opinion on therapeutic patents 2017 03 0827(7) 831-849 doi 10.1080/13543776.2017.1297797
Abstract
INTRODUCTION
TrkA/B/C receptor activation supports growth, survival, and differentiation of discrete neuronal populations during development, adult life, and ageing but also plays numerous roles in human disease onset and progression. Trk-specific inhibitors have therapeutic applications in cancer and pain and thus constitute a growing area of interest in oncology and neurology. There has been substantial growth in the number of structural classes of Trk inhibitors and the number of industrial entrants to the Trk inhibitor field over the past six years. Areas covered: In Part II of this two-part review, the discussion of recent patent literature covering Trk family inhibitors is continued from Part I and clinical research with Trk inhibitors is considered. Expert opinion: Trk has been molecularly targeted for over a decade resulting in the progressive evolution of structurally diversified Trk inhibitors arising from scaffold hopping and HTS efforts. Correspondingly, there have been a growing number of clinical investigations utilizing Trk inhibitors in recent years, with a particular focus on the treatment of NTRK-fusion positive cancers and chronic pain. The observed potential of Trk inhibitors to cause adverse CNS side effects however suggests the need for a more rigorous consideration of BBB permeation capabilities during drug development.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × 3 =

[ HIDE/SHOW ]